The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
Protic Ionic Liquids Based on Decahydroisoquinoline: Lost Superfragility and Ionicity-Fragility Correlation
PILs prove to cover the whole range of IL ionicitiesfrom poor IL to good IL, and even superionic, assessed from the Walden plot, depending on the choice of Brønsted acid. We find that the superfragile character of the parent DHiQ becomes completely suppressed upon conversion to ionicliquid, the initial value m = 128 sinking to m = 45–91 for the ionicliquid. Such values are in the intermediate to fragile